RAFAEL
RUBIO GARCÍA
Profesor titular de universidad
Universidad Autónoma de Madrid
Madrid, EspañaPublicacións en colaboración con investigadores/as de Universidad Autónoma de Madrid (18)
2022
-
Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance
Open Forum Infectious Diseases, Vol. 9, Núm. 11
2019
-
HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study
Scientific Reports, Vol. 9, Núm. 1
2016
2014
-
Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis
Journal of Acquired Immune Deficiency Syndromes, Vol. 66, Núm. 3, pp. 280-287
2010
-
Misindentification of Mycobacterium kumamotonense as M. tuberculosis
Emerging Infectious Diseases
2009
-
HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with virological failure to nucleoside drug combinations
Journal of Antimicrobial Chemotherapy, Vol. 64, Núm. 2, pp. 251-258
-
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-Week analysis
Journal of Acquired Immune Deficiency Syndromes, Vol. 51, Núm. 2, pp. 147-152
-
Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression
Antiviral Therapy, Vol. 14, Núm. 2, pp. 195-201
2008
-
High-density lipoprotein cholesterol and paraoxonase 1 (PON1) genetics and serum PON1 activity in prepubertal children in Spain
Clinical Chemistry and Laboratory Medicine, Vol. 46, Núm. 6, pp. 809-813
-
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV
AIDS, Vol. 22, Núm. 2
2007
-
Análisis de la actividad paraoxonasa (PON1) y de los polimorfismos PON1 192 y PON1 55 en la población prepuberal del Estudio Cuatro Provincias
Clinica e Investigacion en Arteriosclerosis, Vol. 19, Núm. 6, pp. 287-292
2005
-
Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: Frequency, characterization and risk factors
Journal of Antimicrobial Chemotherapy, Vol. 55, Núm. 5, pp. 800-804
2004
-
Clinical, Virologic, and Immunologic Response to Efavirenz- or Protease Inhibitor-Based Highly Active Antiretroviral Therapy in a Cohort of Antiretroviral-Naive Patients with Advanced HIV Infection (EfaVIP 2 Study)
Journal of Acquired Immune Deficiency Syndromes, Vol. 35, Núm. 4, pp. 343-350
2002
-
Dietary patterns among children aged 6-7 y in four Spanish cities with widely differing cardiovascular mortality
European Journal of Clinical Nutrition, Vol. 56, Núm. 2, pp. 141-148
-
High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/μl and opportunistic diseases: The Efa VIP study (Efavirenz in very immunosuppressed patients)
AIDS, Vol. 16, Núm. 11, pp. 1554-1556
-
Influence of birth weight on the apo E genetic determinants of plasma lipid levels in children
Pediatric Research, Vol. 52, Núm. 6, pp. 873-878
-
Metabolic factors in school children population associated with adult cardiovascular mortality. Four provinces study
Medicina Clinica, Vol. 118, Núm. 20, pp. 767-770
2000
-
Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain
AIDS, Vol. 14, Núm. 6, pp. 727-732